ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended bevacizumab reference biologic (Avastin) for subsidy for treating persistent, recurrent or metastatic cervical cancer in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.

Clinical indications, subsidy class and MediShield Life claim limits are provided in the Annex.

Bevacizumab for treating persistent recurrent or metastatic cervical cancer (12 Jul 22) Bevacizumab for treating advanced cervical cancer PES (1 Apr 2022)